David Malcom Rodman sold $879k of MLYS
Chief Medical Officer at Mineralys Therapeutics, Inc.. 55,771 shares at an average of $15.76, traded Apr 1, 2025, filed Apr 3, 2025.
Score components
- +15RoleOfficer
- +23Trade size$879k at market
- +10Share of holdings soldSold 32% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001933414-25-000029, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | MOption exercise Common Stock10b5-1 | +1,606 | $1.08 | $1,734 | 172,475 | Apr 3, 2025 |
| Apr 1, 2025 | SOpen-market sale Common Stock10b5-1 | -30,574 | $15.00 | $459k | 141,901 | Apr 3, 2025 |
| Apr 1, 2025 | SOpen-market sale Common Stock10b5-1 | -2,791 | $16.02 | $45k | 139,110 | Apr 3, 2025 |
| Apr 1, 2025 | SOpen-market sale Common Stock10b5-1 | -22,406 | $16.77 | $376k | 116,704 | Apr 3, 2025 |
| Apr 1, 2025 | MOption exercise Stock Optionderivative10b5-1 | -1,606 | $0.00 | $0 | 114,274 | Apr 3, 2025 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 60Notable | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director, owner | $43M 1,000,000 shares | -11% | |
| 70Notable | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $9.1M 200,000 shares | -24% | |
| 60Notable | Mineralys Therapeutics, Inc. | Alexander M Gold director | $1.6M 34,675 shares | -231% | |
| 56Moderate | Mineralys Therapeutics, Inc. | Daphne Karydas director | $690k 15,000 shares | -100% | |
| 67Notable | Mineralys Therapeutics, Inc. | Adam Scott Levy CFO and Secretary | $5.4M 119,524 shares | -86% | |
| 40Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $644k 15,100 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.